Proteon Therapeutics, Inc. (NASDAQ:PRTO) has been assigned a $2.00 price objective by HC Wainwright in a report released on Wednesday, August 9th. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 48.15% from the stock’s previous close.
Other analysts also recently issued research reports about the stock. Maxim Group set a $6.00 price target on shares of Proteon Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Zacks Investment Research downgraded shares of Proteon Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 17th. Finally, Cowen and Company reiterated a “hold” rating on shares of Proteon Therapeutics in a research note on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $8.00.
Proteon Therapeutics (PRTO) opened at 1.35 on Wednesday. The firm’s market cap is $23.79 million. The firm’s 50-day moving average is $1.37 and its 200 day moving average is $1.52. Proteon Therapeutics has a 12-month low of $1.10 and a 12-month high of $11.45.
Proteon Therapeutics (NASDAQ:PRTO) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.11. Equities research analysts predict that Proteon Therapeutics will post ($1.51) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Proteon Therapeutics, Inc. (PRTO) PT Set at $2.00 by HC Wainwright” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.com-unik.info/2017/08/19/proteon-therapeutics-inc-prto-given-a-2-00-price-target-by-hc-wainwright-analysts-updated.html.
An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC bought a new stake in Proteon Therapeutics, Inc. (NASDAQ:PRTO) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics makes up 0.2% of RA Capital Management LLC’s investment portfolio, making the stock its 22nd largest position. RA Capital Management LLC owned approximately 7.59% of Proteon Therapeutics at the end of the most recent quarter. 41.08% of the stock is owned by institutional investors.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
What are top analysts saying about Proteon Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Proteon Therapeutics Inc. and related companies.